Prostate Cancer Markers

1982 ◽  
pp. 179-190
Author(s):  
T. Ming Chu ◽  
Ming C. Wang ◽  
Ching-li Lee ◽  
Carl S. Killian ◽  
Manabu Kuriyama ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Markers

Simultaneous immunoassays of dual prostate cancer markers using a SERS-based microdroplet channel

2018 ◽  
Vol 119 ◽  
pp. 126-133 ◽  
Author(s):  
Rongke Gao ◽  
Ziyi Cheng ◽  
Xiaokun Wang ◽  
Liandong Yu ◽  
Zhongyi Guo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Markers

scholarly journals Scanometric MicroRNA Array Profiling of Prostate Cancer Markers Using Spherical Nucleic Acid–Gold Nanoparticle Conjugates

2012 ◽  
Vol 84 (9) ◽  
pp. 4153-4160 ◽  
Author(s):  
Ali H. Alhasan ◽  
Dae Y. Kim ◽  
Weston L. Daniel ◽  
Erin Watson ◽  
Joshua J. Meeks ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Nucleic Acid ◽  
Gold Nanoparticle ◽  
Cancer Markers ◽  
Spherical Nucleic Acid

Screening for cancer: is it cost effective?

1993 ◽  
Vol 39 (11) ◽  
pp. 2397-2403 ◽  
Author(s):  
M K Schwartz
Keyword(s):  
Prostate Cancer ◽  
Risk Factor ◽  
Specific Antigen ◽  
Cost Effective ◽  
Ca 125 ◽  
Cancer Markers ◽  
Presumptive Identification ◽  
Previously Treated ◽  
Probability Of Cancer ◽  
Major Emphasis

Abstract Screening is defined as the presumptive identification of unrecognized disease or defect by the application of tests, examinations, or other procedures that can be applied rapidly and carried out in the general population or in individuals at high risk. When considering immunochemical or biochemical cancer markers, it might be more appropriate to describe these tests as risk-factor monitors and introduce the concept of two interpretations of these tests: in asymptomatic populations as indicators of probability of cancer, and in patients with previously treated cancer as predictors of recurrence despite initial treatment described as "curative." The successes of screening with alpha-fetoprotein for hepatocellular carcinoma and with catechol metabolites in neuroblastoma are discussed. The major emphasis will be the possible use of CA 125 and prostate-specific antigen (PSA) in risk-factor assessment of ovarian cancer and prostate cancer, respectively. It is important to understand in what context a PSA value > 10 micrograms/L indicates a 67% probability of cancer.

Profiling of Antibody Production against Xenograft-released Proteins by Protein Microarrays Discovers Prostate Cancer Markers

2011 ◽  
Vol 11 (2) ◽  
pp. 728-735 ◽  
Author(s):  
Flip H. Jansen ◽  
Angelique van Rijswijk ◽  
Wilma Teubel ◽  
Wytske M. van Weerden ◽  
Suzanne Reneman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Antibody Production ◽  
Protein Microarrays ◽  
Cancer Markers

scholarly journals GOLPH2 and MYO6: Putative prostate cancer markers localized to the Golgi apparatus

The Prostate ◽  
2008 ◽  
Vol 68 (13) ◽  
pp. 1387-1395 ◽  
Author(s):  
Shuanzeng Wei ◽  
Thomas A. Dunn ◽  
William B. Isaacs ◽  
Angelo M. De Marzo ◽  
Jun Luo
Keyword(s):  
Prostate Cancer ◽  
Golgi Apparatus ◽  
Cancer Markers
Sign in / Sign up

Export Citation Format

Share Document